MENU
+Compare
CYTK
Stock ticker: NASDAQ
AS OF
Sep 12, 02:27 PM (EDT)
Price
$51.98
Change
-$1.34 (-2.51%)
Capitalization
6.37B

CYTK Cytokinetics Forecast, Technical & Fundamental Analysis

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more

Industry: #Biotechnology
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CYTK with price predictions
Sep 11, 2025

CYTK's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CYTK turned positive on September 02, 2025. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on CYTK as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CYTK moved above its 50-day moving average on September 02, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 156 cases where CYTK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CYTK broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (20.431). P/E Ratio (0.000) is within average values for comparable stocks, (53.322). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.177). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (71.942) is also within normal values, averaging (335.915).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CYTK is expected to report earnings to rise 40.18% to -157 cents per share on October 30

Cytokinetics CYTK Stock Earnings Reports
Q3'25
Est.
$-1.57
Q2'25
Beat
by $0.30
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.04
Q3'24
Missed
by $0.13
The last earnings report on August 07 showed earnings per share of -112 cents, beating the estimate of -141 cents. With 352.90K shares outstanding, the current market capitalization sits at 6.37B.
A.I. Advisor
published General Information

General Information

a company which engages in discovery and development of small molecule drug therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
350 Oyster Point Boulevard
Phone
+1 650 624-3000
Employees
564
Web
https://www.cytokinetics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BSCFX31.040.50
+1.65%
Baron Small Cap Retail
FFMMX62.090.47
+0.76%
American Funds American Mutual 529-F-2
SGGCX65.24N/A
N/A
DWS Large Cap Focus Growth C
LYRBX29.66N/A
N/A
Lyrical US Value Equity Investor
TPYIX9.29N/A
N/A
Touchstone Sands Capital Intl Gr Eq I

CYTK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IONS. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+2.42%
IONS - CYTK
62%
Loosely correlated
+0.06%
MLYS - CYTK
54%
Loosely correlated
-3.63%
CRNX - CYTK
45%
Loosely correlated
-3.61%
ARWR - CYTK
44%
Loosely correlated
+2.87%
ROIV - CYTK
44%
Loosely correlated
+4.65%
More